The economic burden of lung cancer and the associated costs of treatment failure in the United States

Lung Cancer

Volumn 50, Issue 2, 2005, Pages 143-154

  Kutikova, Lucie ^a   Bowman, Lee ^a   Chang, Stella ^b   Long, Stacey R ^b   Obasaju, Coleman ^a   Crown, William H ^b  

^a ELI LILLY AND COMPANY   (United States)

^b MEDSTAT GROUP   (United States)

Author keywords

Costs; Lung cancer; Non small cell lung cancer; Resource use; Small cell lung cancer; Treatment failure

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; CHILD; COHORT ANALYSIS; DATA BASE; DISEASE SEVERITY; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH SERVICE; HOSPITAL COST; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INFANT; LABORATORY TEST; LUNG CANCER; MALE; NEWBORN; OUTPATIENT; PRIORITY JOURNAL; REIMBURSEMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL ANALYSIS; TREATMENT FAILURE; UNITED STATES;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COST OF ILLNESS; FEMALE; GEOGRAPHY; HEALTH CARE COSTS; HEALTH SERVICES; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INSURANCE, HEALTH; LUNG NEOPLASMS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 26444559096     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.06.005     Document Type: Article

References (28)

1. American Cancer Society. Cancer facts and figures 2003. American Cancer Society, 2003.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide IARC CancerBase No. 5. version 2.0, IARC Press, Lyon, 2004. Available at: http://www-depdb.iarc.fr/globocan/GLOBOframe. htm.
3. M.A. Rosenthal, P.J. Webster, V.J. Gebski, R.C. Stuart-Harris, A.O. Langlands, and J. Boyages The cost of treating small cell lung cancer Med J Aust 156 9 1992 605 610
4. W.K. Evans, B.P. Will, J.M. Berthelot, and M.C. Wolfson The economics of lung cancer management in Canada Lung Cancer 14 1 1996 19 29
5. M.L. Brown, and L. Fintor The economic burden of cancer Greenwald Cancer Prevention and Control 1995 Marcel Dekker, Inc New York
6. M.L. Brown, G.F. Riley, N. Schussler, and R. Etzioni Estimating health care costs related to cancer treatment from SEER-Medicare data Med Care 40 Suppl 8 2002 IV-104-117
7. B.E. Hillner, K. McDonald, C.E. Desch, T.J. Smith, L.T. Penberthy, and P. Maddox Costs of care associated with non-small-cell lung cancer in a commercially insured cohort J Clin Oncol 16 1998 1420 1424
8. B.H. Fireman, C.P. Quesenberry, C.P. Somkin, A.S. Jacobson, D. Baer, and D. West Cost of care for cancer in a health maintenance organization Health Care Financing Rev 18 1997 51 76
9. W. Du, J.H. Reeves, S. Gadgeel, J. Abrams, and W.P. Peters Cost-effectiveness and lung cancer clinical trials Cancer 98 2003 1491 1496
10. M.S. Baker, L.G. Kessler, N. Urban, and R.C. Smucker Estimating the treatment costs of breast and lung cancer Med Care 29 1991 40 49
11. O. Shoheiber, J.J. Schrogie, and N. Johnson Non-small cell lung cancer: a cost of illness study Pharmacotherapy 16 1996 136 (abstr 72)
12. E. Oliver, J. Killen, G. Kiebert, J. Hutton, R. Hall, and B. Higgins Treatment pathways, resource use and costs in the management of small cell lung cancer Thorax 56 2001 785 790
13. S. Chang, S.R. Long, L. Kutikova, L. Bowman, D. Finley, and W.H. Crown Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999-2000 J Clin Oncol 22 2004 3524 3530
14. W. D'Hoore, A. Bouckaert, and C. Tilquin Practical considerations on the use of the Charlson Comorbidity Index with administrative databases J Clin Epidemiol 49 1996 1429 1433
15. C.A. Barnes Disease staging: a clinically oriented dimension of case mix Am Med Rec Assoc 56 1985 22 27
16. N. Duan Smearing estimate: a nonparametric retransformation method JASA 78 1983 605 610
17. M.L. Brown, J. Lipscomb, and C. Snyder The burden of illness of cancer: economic cost and quality of life Annu Rev Public Health 22 2001 91 113
18. J.H. Burkhardt, and J.H. Sunshine Core-needle and surgical breast biopsy: comparison of three methods of assessing cost Radiology 212 1999 181 188
19. J.L. Warren, M.L. Brown, M.P. Fay, N. Schussler, A.L. Potosky, and G.F. Riley Cost of treatment for elderly women with early-stage breast cancer in fee-for-service settings J Clin Oncol 20 2002 307 316
20. A. Barnett, H. Birnbaum, P.-Y. Cremieux, M. Fendrick, and M. Slavin The costs of cancer to a major employer in the United States: a case-control analysis Am J Manag Care 6 2000 1243 1251
21. M. Boyer The economics of lung cancer Lung Cancer 14 1996 13 17
22. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Available at: http://www.nccn.org/professionals/ physician_gls/default.asp. Accessed 18 January 2005.
23. T.L. Winton, R. Livingston, D. Johnson, J. Rigas, Y. Cormier, and C. Butts A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non-small cell lung cancer (NSCLC) Intergroup JBR.10 J Clin Oncol 22 14S 2004 (abstr 7018)
24. G.M. Strauss, J. Herndon, M.A. Maddaus, D.W. Johnstone, E.A. Johnson, and D.M. Watson Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of cancer and leukemia group B (CALGB) protocol 9633 J Clin Oncol 22 14S 2004 (abstr 7019)
25. J.H. Schiller, D. Harrington, C.P. Belani, C. Langer, A. Sandler, and J. Krook Comparison of four chemotherapy regimens for advanced non-small cell lung cancer N Engl J Med 346 2002 92 98
26. F.A. Shepherd, J. Pereira, T.E. Ciuleanu, E.H. Tan, V. Hirsh, and S. Thongprasert A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure on 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial J Clin Oncol 22 14S 2004 622s (abstr 7022)
27. N. Hanna, F.A. Shepherd, F.V. Fossela, J. Pereira, F. De Marinis, and J. von Pawel Randomized phase III trial of premetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy J Clin Oncol 22 9 2004 1589 1597
28. American Cancer Society. What is lung cancer? Revised April 2004. Available at: http://www.cancer.org/docroot/CRI/content/ CRI_2_2_1X_What_is_lung_cancer_26.asp?sitearea=. Accessed 17 September 2004.